AU2003303231A1 - Benzoxazines and derivatives thereof as inhibitors of pi3ks - Google Patents

Benzoxazines and derivatives thereof as inhibitors of pi3ks

Info

Publication number
AU2003303231A1
AU2003303231A1 AU2003303231A AU2003303231A AU2003303231A1 AU 2003303231 A1 AU2003303231 A1 AU 2003303231A1 AU 2003303231 A AU2003303231 A AU 2003303231A AU 2003303231 A AU2003303231 A AU 2003303231A AU 2003303231 A1 AU2003303231 A1 AU 2003303231A1
Authority
AU
Australia
Prior art keywords
pi3ks
benzoxazines
inhibitors
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303231A
Other languages
English (en)
Inventor
Rocco Dean Gogliotti
Keri Lynn Muccioli
Kimberly Suzanne Para
Melean Visnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2003303231A1 publication Critical patent/AU2003303231A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003303231A 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks Abandoned AU2003303231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43522702P 2002-12-20 2002-12-20
US60/435,227 2002-12-20
PCT/IB2003/005887 WO2004056820A1 (en) 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks

Publications (1)

Publication Number Publication Date
AU2003303231A1 true AU2003303231A1 (en) 2004-07-14

Family

ID=32682185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303231A Abandoned AU2003303231A1 (en) 2002-12-20 2003-12-10 Benzoxazines and derivatives thereof as inhibitors of pi3ks

Country Status (8)

Country Link
US (1) US20040138199A1 (OSRAM)
EP (1) EP1581529A1 (OSRAM)
JP (1) JP2006512357A (OSRAM)
AU (1) AU2003303231A1 (OSRAM)
BR (1) BR0317572A (OSRAM)
CA (1) CA2510851A1 (OSRAM)
MX (1) MXPA05006742A (OSRAM)
WO (1) WO2004056820A1 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050026992A1 (en) * 2003-07-28 2005-02-03 Sasmal Badal Kumar Treatment and prevention of cardiovascular events
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
CA2566436C (en) * 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
MX2007002604A (es) 2004-09-03 2007-04-25 Applied Research Systems Azolidinonas de piridina metileno y uso de las mismas.
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AU2006280074A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
WO2007023186A1 (en) 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
MX2008003189A (es) * 2005-09-07 2008-03-18 Serono Lab Inhibidores de fosfoinositido 3-cinasa para el tratamiento de endometriosis.
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
NZ568860A (en) * 2005-12-09 2012-09-28 Metaproteomics Llc Protein kinase modulation by hops and acacia products
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
ZA200904857B (en) 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
WO2009026346A1 (en) * 2007-08-20 2009-02-26 Targegen Inc. Thiazolidine compounds, and methods of making and using same
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20110115160A (ko) 2009-02-12 2011-10-20 메르크 세로노 에스. 에이. 2-모르폴리노-피리도〔3,2-ｄ〕피리미딘
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
NZ596552A (en) * 2009-05-26 2014-02-28 Exelixis Inc Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
JP5735526B2 (ja) 2009-11-13 2015-06-17 メルク セローノ ソシエテ アノニム 三環式ピラゾールアミン誘導体
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
TR201810944T4 (tr) 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
NZ720004A (en) 2013-11-18 2020-03-27 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
ES2707726T3 (es) * 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3694511A1 (en) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2025161263A1 (zh) * 2024-01-31 2025-08-07 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
EP1278748B1 (en) * 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
BR0312650A (pt) * 2002-07-10 2005-05-03 Applied Research Systems Derivados de benzeno fundido azolidinona-vinila
AU2003225669A1 (en) * 2002-09-26 2004-04-19 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof

Also Published As

Publication number Publication date
CA2510851A1 (en) 2004-07-08
EP1581529A1 (en) 2005-10-05
BR0317572A (pt) 2005-11-22
MXPA05006742A (es) 2005-09-08
JP2006512357A (ja) 2006-04-13
US20040138199A1 (en) 2004-07-15
WO2004056820A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003303231A1 (en) Benzoxazines and derivatives thereof as inhibitors of pi3ks
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003251559A1 (en) Heterocyclic inhibitors of kinases
AU2003237121A1 (en) Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003235676A1 (en) Tricyclic-bis-enone derivatives and methods of use thereof
AU2003256297A1 (en) Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003261449A1 (en) Compositions for rna interference and methods of use thereof
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2002228316A1 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2003218758A1 (en) Derivatives of 1-phenyl-3-phenylpyrazole as herbicides
AU2003293356A1 (en) Dihydropyridinone derivatives as hne inhibitors
AU2003243318A1 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003300692A1 (en) Stable formulations of ace inhibitors and methods for preparation thereof
AU2003210983A1 (en) Kinase inhibitors and methods of use thereof
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2003214609A1 (en) Derivatives of isoflavones
AU2003268464A1 (en) INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase